NASDAQ:MRUS - Merus Stock Price, Forecast & News

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Merus.

6 Wall Street analysts have issued 1-year target prices for Merus' stock. Their forecasts range from $16.00 to $35.00. On average, they expect Merus' share price to reach $24.00 in the next year. This suggests a possible upside of 38.3% from the stock's current price. View Analyst Price Targets for Merus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Press coverage about MRUS stock has trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merus earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Merus.

Merus saw a increase in short interest in January. As of January 31st, there was short interest totalling 436,600 shares, an increase of 21.1% from the January 15th total of 360,500 shares. Based on an average daily trading volume, of 119,000 shares, the short-interest ratio is presently 3.7 days. Currently, 2.4% of the shares of the company are short sold. View Merus' Current Options Chain.

Some companies that are related to Merus include BELLUS Health (BLUSF), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR), TG Therapeutics (TGTX), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Innoviva (INVA), Nabriva Therapeutics (NBRV), Theravance Biopharma (TBPH), ZEALAND PHARMA/S (ZEAL), Dicerna Pharmaceuticals (DRNA), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL) and Intra-Cellular Therapies (ITCI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Viking Therapeutics (VKTX), AT&T (T), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), GlycoMimetics (GLYC) and Idera Pharmaceuticals (IDRA).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (13.54%), EcoR1 Capital LLC (7.34%), Driehaus Capital Management LLC (6.13%), Platinum Investment Management Ltd. (0.73%), Oxford Asset Management LLP (0.22%) and Old West Investment Management LLC (0.11%). Company insiders that own Merus stock include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Institutional Ownership Trends for Merus.

MRUS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Tower Research Capital LLC TRC . View Insider Buying and Selling for Merus.

MRUS stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Driehaus Capital Management LLC, Oxford Asset Management LLP, Platinum Investment Management Ltd., Old West Investment Management LLC, Renaissance Technologies LLC, Marshall Wace LLP and Acadian Asset Management LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Merus.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $17.35.

Merus has a market capitalization of $406.13 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.

The official website for Merus is http://www.merus.nl/.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]